Tag Archives: AbbVie
By Pharm Exec | Published: October 23, 2014
The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation, says research and consulting firm GlobalData.
By Pharm Exec | Published: July 22, 2014
AbbVie’s recent $54 billion acquisition of Shire and subsequent relocation to Ireland will mean substantial tax savings for the US pharmaceutical giant, according to analysts at research and consulting firm GlobalData.
By Tom Norton | Published: June 27, 2014
As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
By Pharm Exec | Published: February 28, 2014
While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
By Reflector | Published: October 16, 2013
Who is Trying to Stop the European Transparency Bandwagon? Reflector, EPE, October 14 2013 The data-transparency bandwagon is rolling rapidly across Europe, energetically propelled by regulators, health campaigners, and generic manufacturers. Much of the research-based industry is stepping out of the way of what looks like an unstoppable juggernaut, hoping at best to nudge it […]